Chemosaturation with percutaneous hepatic perfusion in unresectable hepatic metastases

Evan Glazer, Jonathan S. Zager

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Background: In patients with hepatic metastases from solid-organ malignancies, surgical resection may be a potentially curative option, but it is not possible in most cases. Chemosaturation with percutaneous hepatic perfusion was developed for the management of unresectable metastases to the liver. Methods: Relevant medical literature was summarized with regard to the outcomes and limitations of chemosaturation with percutaneous hepatic perfusion. Results: Six articles were identified that contained data on 91 individuals who received chemosaturation with percutaneous hepatic perfusion. More than 60% of these study patients were diagnosed with ocular melanoma. The overall response rate was 48% and the rate of disease control was 90%. Chemosaturation with percutaneous hepatic perfusion improved the rates of overall and hepatic progression-free survival (PFS). The data are limited but suggest that the rate of PFS was improved in study patients with isolated melanoma hepatic metastases who received chemosaturation with percutaneous hepatic perfusion compared with those assigned to standard care. Conclusions: Our results suggest that chemosaturation with percutaneous hepatic perfusion produces favorable tumor response rates in select individuals with unresectable hepatic metastases from multiple primary cancers, particularly ocular and cutaneous melanomas. Data from a single randomized clinical trial have also shown that chemosaturation with percutaneous hepatic perfusion can affect hepatic PFS in certain patients.

Original languageEnglish (US)
Pages (from-to)96-101
Number of pages6
JournalCancer Control
Volume24
Issue number1
DOIs
StatePublished - Jan 1 2017

Fingerprint

Perfusion
Neoplasm Metastasis
Liver
Disease-Free Survival
Melanoma
Eye Neoplasms
Skin Neoplasms
Neoplasms
Randomized Controlled Trials

All Science Journal Classification (ASJC) codes

  • Hematology
  • Oncology

Cite this

Chemosaturation with percutaneous hepatic perfusion in unresectable hepatic metastases. / Glazer, Evan; Zager, Jonathan S.

In: Cancer Control, Vol. 24, No. 1, 01.01.2017, p. 96-101.

Research output: Contribution to journalArticle

@article{088419daf46047be88ae5820f55cc1df,
title = "Chemosaturation with percutaneous hepatic perfusion in unresectable hepatic metastases",
abstract = "Background: In patients with hepatic metastases from solid-organ malignancies, surgical resection may be a potentially curative option, but it is not possible in most cases. Chemosaturation with percutaneous hepatic perfusion was developed for the management of unresectable metastases to the liver. Methods: Relevant medical literature was summarized with regard to the outcomes and limitations of chemosaturation with percutaneous hepatic perfusion. Results: Six articles were identified that contained data on 91 individuals who received chemosaturation with percutaneous hepatic perfusion. More than 60{\%} of these study patients were diagnosed with ocular melanoma. The overall response rate was 48{\%} and the rate of disease control was 90{\%}. Chemosaturation with percutaneous hepatic perfusion improved the rates of overall and hepatic progression-free survival (PFS). The data are limited but suggest that the rate of PFS was improved in study patients with isolated melanoma hepatic metastases who received chemosaturation with percutaneous hepatic perfusion compared with those assigned to standard care. Conclusions: Our results suggest that chemosaturation with percutaneous hepatic perfusion produces favorable tumor response rates in select individuals with unresectable hepatic metastases from multiple primary cancers, particularly ocular and cutaneous melanomas. Data from a single randomized clinical trial have also shown that chemosaturation with percutaneous hepatic perfusion can affect hepatic PFS in certain patients.",
author = "Evan Glazer and Zager, {Jonathan S.}",
year = "2017",
month = "1",
day = "1",
doi = "10.1177/107327481702400116",
language = "English (US)",
volume = "24",
pages = "96--101",
journal = "Cancer Control",
issn = "1073-2748",
publisher = "H. Lee Moffitt Cancer Center and Research Institute",
number = "1",

}

TY - JOUR

T1 - Chemosaturation with percutaneous hepatic perfusion in unresectable hepatic metastases

AU - Glazer, Evan

AU - Zager, Jonathan S.

PY - 2017/1/1

Y1 - 2017/1/1

N2 - Background: In patients with hepatic metastases from solid-organ malignancies, surgical resection may be a potentially curative option, but it is not possible in most cases. Chemosaturation with percutaneous hepatic perfusion was developed for the management of unresectable metastases to the liver. Methods: Relevant medical literature was summarized with regard to the outcomes and limitations of chemosaturation with percutaneous hepatic perfusion. Results: Six articles were identified that contained data on 91 individuals who received chemosaturation with percutaneous hepatic perfusion. More than 60% of these study patients were diagnosed with ocular melanoma. The overall response rate was 48% and the rate of disease control was 90%. Chemosaturation with percutaneous hepatic perfusion improved the rates of overall and hepatic progression-free survival (PFS). The data are limited but suggest that the rate of PFS was improved in study patients with isolated melanoma hepatic metastases who received chemosaturation with percutaneous hepatic perfusion compared with those assigned to standard care. Conclusions: Our results suggest that chemosaturation with percutaneous hepatic perfusion produces favorable tumor response rates in select individuals with unresectable hepatic metastases from multiple primary cancers, particularly ocular and cutaneous melanomas. Data from a single randomized clinical trial have also shown that chemosaturation with percutaneous hepatic perfusion can affect hepatic PFS in certain patients.

AB - Background: In patients with hepatic metastases from solid-organ malignancies, surgical resection may be a potentially curative option, but it is not possible in most cases. Chemosaturation with percutaneous hepatic perfusion was developed for the management of unresectable metastases to the liver. Methods: Relevant medical literature was summarized with regard to the outcomes and limitations of chemosaturation with percutaneous hepatic perfusion. Results: Six articles were identified that contained data on 91 individuals who received chemosaturation with percutaneous hepatic perfusion. More than 60% of these study patients were diagnosed with ocular melanoma. The overall response rate was 48% and the rate of disease control was 90%. Chemosaturation with percutaneous hepatic perfusion improved the rates of overall and hepatic progression-free survival (PFS). The data are limited but suggest that the rate of PFS was improved in study patients with isolated melanoma hepatic metastases who received chemosaturation with percutaneous hepatic perfusion compared with those assigned to standard care. Conclusions: Our results suggest that chemosaturation with percutaneous hepatic perfusion produces favorable tumor response rates in select individuals with unresectable hepatic metastases from multiple primary cancers, particularly ocular and cutaneous melanomas. Data from a single randomized clinical trial have also shown that chemosaturation with percutaneous hepatic perfusion can affect hepatic PFS in certain patients.

UR - http://www.scopus.com/inward/record.url?scp=85011565162&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85011565162&partnerID=8YFLogxK

U2 - 10.1177/107327481702400116

DO - 10.1177/107327481702400116

M3 - Article

VL - 24

SP - 96

EP - 101

JO - Cancer Control

JF - Cancer Control

SN - 1073-2748

IS - 1

ER -